Marianne Wigernes Strand

Marianne Wigernes Strand

Auto-generated profile, based on publicly available information

Marianne Wigernes Strand

Dept. of Infectious Diseases, Østfold Hospital, Kalnes, Norway Marianne. Wigernes

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 May 2022 in Journal of Infection
Verified
Journal Article
Open access
SSSigne Søvik
Signe Søvik
ABAndreas Barratt-Due
Andreas Barratt-Due
TKTrine Kåsine
Trine Kåsine
TOTheresa Olasveengen
Theresa Olasveengen
MSMarianne Wigernes Strand
Marianne Wigernes Strand
INIngvild Nordøy
Ingvild Nordøy
To determine the incidence and characteristics of superinfections in mechanically ventilated COVID-19 patients, and the impact of dexamethasone as standard therapy. This multicentre, observational, retrospective study included patients ≥ 18 years admitted from March 1st 2020 to January 31st 2021 with COVID-19 infection who received mechanical ventilation. Patient characteristics, clinical characteristics, therapy and survival were examined. 155/156 patients (115 men, mean age 62 years, range 26-84 years) were included. 67 patients (43%) had 90 superinfections, pneumonia dominated (78%). Superinfections were associated with receiving dexamethasone (66% vs 32%, p<0.0001), autoimmune disease (18% vs 5.7%, p<0.016) and with longer ICU stays (26 vs 17 days, p<0,001). Invasive fungal infections were reported exclusively in dexamethasone-treated patients [8/67 (12%) vs 0/88 (0%), p<0.0001]. Unadjusted 90-day survival did not differ between patients with or without superinfections (64% vs 73%, p=0.25), but was lower in patients receiving dexamethasone versus not (58% vs 78%, p=0.007). In multiple regression analysis, superinfection was associated with dexamethasone use [OR 3.7 (1.80–7.61), p<0.001], pre-existing autoimmune disease [OR 3.82 (1.13–12.9), p=0.031] and length of ICU stay [OR 1.05 p<0.001]. In critically ill COVID-19 patients, dexamethasone as standard of care was strongly and independently associated with superinfections.